Shares of Axovant Sciences Ltd. (NYSE: AXON) tumbled $2.16 to close at $15.14 after rival Lundbeck reported disappointing results from a Phase III study of the Alzheimer's treatment idalopirdine.
Axovant Sciences falls on rival's disappointing data
September 22, 2016 at 18:11 PM EDT
